XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia
Authors:
- Vicent M. GuillemVGVicent M. Guillem
- Francisco CervantesFCFrancisco Cervantes
- Jesús MartínezJMJesús Martínez
- Alberto Alvarez‐LarránAAAlberto Alvarez‐Larrán
- María ColladoMCMaría Collado
- Mireia CamósMCMireia Camós
- Anna SuredaASAnna Sureda
- Margherita MaffioliMMMargherita Maffioli
- Juan‐Carlos Hernández‐BoludaJHJuan‐Carlos Hernández‐Boluda
Open Access
- 23 June 2010
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 85 (7) , 482-486
Abstract
Chronic myeloid leukemia (CML) is driven by the BCR‐ABL protein, which promotes the proliferation and viability of the leukemic cells. Moreover, BCR‐ABL induces genomic instability that can contribute to the emergence of resistant clones to the ABL kinase inhibitors. It is currently unknown whether the inherited individual capability to repair DNA damage could affect the treatment results. To address this, a comprehensive analysis of single nucleotide polimorfisms (SNPs) on the nucleotide excision repair (NER) genes (ERCC2‐ERCC8, RPA1‐RPA3, LIG1, RAD23B, XPA, XPC) was performed in 92 chronic phase CML patients treated with imatinib upfront. ERCC5 and XPC SNPs correlated with the response to imatinib. Haplotype analysis of XPC showed that the wild‐type haplotype (499C‐939A) was associated with a better response to imatinib. Moreover, the 5‐year failure free survival for CA carriers was significantly better than that of the non‐CA carriers (98% vs. 73%; P = 0.02). In the multivariate logistic model with genetic data and clinical covariates, the hemoglobin (Hb) level and the XPC haplotype were independently associated with the treatment response, with patients having a Hb ≤11 g/dl (Odds ratio [OR] = 5.0, 95% confidence interval [CI] = 1.5–16.1) or a non‐CA XPC haplotype (OR = 4.1, 95% CI = 1.6–10.6) being at higher risk of suboptimal response/treatment failure. Our findings suggest that genetic polymorphisms in the NER pathway may influence the results to imatinib treatment in CML. Am. J. Hematol., 2010.Keywords
This publication has 27 references indexed in Scilit:
- BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death thresholdLeukemia, 2008
- Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease ProgressionJournal of Clinical Oncology, 2008
- STI571 reduces NER activity in BCR/ABL-expressing cellsMutation Research - Genetic Toxicology and Environmental Mutagenesis, 2008
- Chronic myeloid leukaemia as a model of disease evolution in human cancerNature Reviews Cancer, 2007
- XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancerMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007
- Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid LeukemiaClinical Cancer Research, 2006
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistanceBlood, 2006
- Clinical resistance to imatinib: mechanisms and implicationsHematology/Oncology Clinics of North America, 2004
- The biology of CML blast crisisBlood, 2004